



Urokinase-Type Plasminogen Activator (PLAU) Antibody

Catalogue No.:abx033923









PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.

Target: Urokinase-Type Plasminogen Activator (PLAU)

Clonality: Polyclonal

Reactivity: Human

Tested Applications: ELISA, WB, IHC, IF/ICC, FCM

Host: Rabbit

Datasheet

Version: 4.0.0 Revision date: 20 Jun 2025



Recommended dilutions: WB: 1/1000, IHC-P: 1/10 - 1/50, IF/ICC: 1/10 - 1/50, FCM: 1/10 - 1/50. Not tested in IHC-F. Optimal

dilutions/concentrations should be determined by the end user.

Conjugation: Unconjugated

Immunogen: KLH-conjugated synthetic peptide between 396-426 amino acids from the C-terminal region of

human Urokinase (PLAU).

Isotype: IgG

Form: Liquid

Purification: Purified through a protein G column, eluted with high and low pH buffers and neutralized

immediately, followed by dialysis against PBS.

Storage: Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

UniProt Primary AC: P00749 (UniProt, ExPASy)

KEGG: hsa:5328

String: 9606.ENSP00000361850

Molecular Weight: Calculated MW: 48.5 kDa

Buffer: PBS containing 0.09% sodium azide.

Note: THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC,

THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL

CONSUMPTION.